tag@treatmentactiongroup.org

Letters

TAG Comment on Penalties Relating to the ClinicalTrials.gov Data Bank

  • Chad Cipiti
Read TAG's comment on The Food and Drug Administration (FDA) Notice: Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank; Draft Guidance for Food and Drug Administration Staff, Responsible Parties, and Submitters of Certain Applications and Submissions to the FDA.
Read more

Right to Science Submission – October, 2018

  • Chad Cipiti
The right to enjoy the benefits of scientific progress and its applications is a fundamental human right and one of the central pillars of TAG's advocacy to promote TB research and access to its benefits. The right is enshrined in Article 27 of the Universal Declaration of Human Rights and further articulated in Article 15 of the International Covenant on Economic, Social, and Cultural Rights (ICESCR).
Read more

TB, Human Rights, and Universal Periodic Review

  • Chad Cipiti
Universal Periodic Review (UPR) is a process through which the human rights record of each United Nations member state is reviewed by other countries every five years. As a civil society organization, TAG regularly writes and submits these UPR reports analyzing the TB situations in UN member states, and you can review our UPR reports on this page.
Read more

Activists: Call On Your Countries To Use BDQ-Based Regimens to Treat TB

  • Chad Cipiti
GCTA, TAG, and DR-TB STAT developed this letter template to help activists to call for bedaquiline-based, injectable-free regimens in their countries. Please download this template letter here and use it in your country to advocate for the best care possible for people with drug-resistant TB.
Read more

Strengthening TB Research in NIAID’s Tuberculosis Strategic Plan

  • Chad Cipiti
Treatment Action Group (TAG) submitted comments to the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) in response to a public request for information (RFI) to inform NIAID's Tuberculosis Strategic Plan on supporting TB research and development (R&D).
Read more

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications

  • Chad Cipiti
Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Read more
Back To Top